Elan Overview

  • Founded
  • 1969
Founded
  • Status
  • Acquired/​Merged
  • Employees
  • 1,500
Employees
  • Latest Deal Type
  • M&A
  • Financing Rounds
  • 3
  • Investments
  • 20

Elan General Information

Description

Operator of a neuroscience-based biotechnology company. The company is organized into two business units, BioNeurology and Elan Drug Technologies enabling it to develop and manufacture innovative pharmaceuticals for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease and autoimmune diseases, including multiple sclerosis and Crohn's disease.

Contact Information

Website
www.elan.com
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Acquirer
Perrigo Company
Primary Office
  • Lincoln House, Lincoln Place
  • Dublin 2
  • Ireland
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Elan Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Elan‘s full profile, request access.

Request a free trial

Elan Patents

  • 1,886

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 8

    Granted

  • 1

    Pending

  • 000

    Expiring in next 12 mo

Elan Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20160024071-A1 Inhibitors of lrrk2 kinase activity Abandoned 15-Mar-2013 0000000000
US-20180258083-A1 Inhibitors of lrrk2 kinase activity Abandoned 15-Mar-2013 0000000000
EP-2968995-B1 Inhibitors of lrrk2 kinase activity Active 15-Mar-2013 0000000000
EP-2968995-A1 Inhibitors of lrrk2 kinase activity Granted 15-Mar-2013 0000000000
EP-2968995-A4 Inhibitors of lrrk2 kinase activity Granted 15-Mar-2013 C07D417/12
To view Elan’s complete patent history, request access »

Elan Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Elan Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Elan‘s full profile, request access.

Request a free trial

Elan Investments & Acquisitions (20)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000000000 29-Oct-2018 00000 0000 00.000 Distributors (Healthcare)
000000000000 08-Sep-2015 00000 0000 0000 Drug Discovery
000* 26-Jun-2014 0000000000 Media and Information Services (B2B)
000000000 000 29-May-2013 00000 0000 0000 Biotechnology 0. 000000
AOP Orphan Pharmaceuticals 20-May-2013 Merger/Acquisition 00000 Distributors (Healthcare) 0. 000000
You’re viewing 5 of 20 investments and acquisitions. Get the full list »

Elan Subsidiaries (2)

Company Name Industry Location Founded
AOP Orphan Pharmaceuticals Distributors (Healthcare) Vienna, Austria 1996
000000 Pharmaceuticals Menlo Park, CA 0000
To view Elan’s complete subsidiaries history, request access »

Elan Exits (8)

Company Name Exit Date Exit Type Exit Size Status Buyers
000000000000 00000 08-Sep-2015 00000 00000 00 0000 Completed
  • 9 buyers
00000000 (00000000 06-Jun-2012 000000000000000000 Completed
  • 0000
000000000000 00000 25-May-2011 00000 00000 00 0000 Completed
  • 0000
0000000 01-Jan-2004 00000 0000000 Completed
  • 2 buyers
HepaSense 14-Jan-2000 Joint Venture Completed
  • 2 buyers
You’re viewing 5 of 8 exits. Get the full list »